TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET
Company Participants
Jenna Bosco - Senior Vice President of Corporate Communications
Michael Weiss - Chairman, President, and Chief Executive Officer
Adam Waldman - Chief Commercialization Officer
Sean Power - Chief Financial Officer
Conference Call Participants
Edward White - H.C. Wainright
Roger Song - Jefferies
Mayank Mamtani - B. Riley Securities
Eric Joseph - JPMorgan
Prakhar Agrawal - Cantor Fitzgerald
Matt Kaplan - Ladenburg Thalmann
Mike DiFiore - Evercore ISI
Operator
Greetings, and welcome to the TG Therapeutics Third Quarter Earnings Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jenna Bosco. Thank you, Jenna. You may begin.
Jenna Bosco
Thank you. Welcome, everyone, and thanks for joining us this morning. I'm Jenna Bosco, and with me today to discuss the third quarter of 2023 financial results are Michael Weiss, our Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercialization Officer; and Sean Power, our Chief Financial Officer. Following our safe harbor statement, Mike will provide an overview of our recent corporate developments. Adam will share an update on our commercialization efforts and Sean will give an overview of our financial results before turning the call over to the operator to begin the Q&A session.
Before we begin, I'd like to remind everyone that we will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about our anticipated future operating and financial performance, including sales performance, projected regulatory milestones, revenue guidance, clinical development plans and expectations for our future -- for our marketed products. TG cautions that these forward-looking statements are subject to risks that may cause our actual results to differ materially from those indicated. Factors that may affect TG Therapeutics' operations include various risk factors that can be found in our SEC filings.
In addition, any forward-looking statements made on this call represent our views only as of today, and should not be relied upon as representing our views as of any later date. We specifically disclaim any obligation to update or revise any forward-looking statements. This conference call is being recorded for audio rebroadcast on TG's website, www.tgtherapeutics.com, where it will be available for the next 30 days.
Now I'd like to turn the call over to Mike Weiss, our CEO.